Center-Authored Papers

Filters: Author is Urban, Nicole  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Z
Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban ND, Mor G, Bast RC, Moore LE et al..  2011.  A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.. Cancer prevention research (Philadelphia, Pa.). 4(3):375-83. Abstract
Y
Yu-Rice Y, Edassery SL, Urban ND, Hellstrom I, Hellstrom KE, Deng Y, Li Y, Luborsky J.  2016.  Selenium Binding Protein 1 autoantibodies in ovarian disorders and ovarian cancer.. Reproduction (Cambridge, England). Abstract
W
Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban ND, Drescher CW, Knudsen BS, Tewari M.  2009.  Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries.. PloS one. 4(4):e5311. Abstract
Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, Urban ND, Lubman DM.  2015.  Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.. PloS one. 10(3):e0121112. Abstract
Wang H, Li Z-Y, Liu Y, Persson J, Beyer I, Möller T, Koyuncu D, Drescher MR, Strauss R, Zhang X-B et al..  2011.  Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.. Nature medicine. 17(1):96-104. Abstract
V
Ventura AP, Radhakrishnan S, Green A, Rajaram SK, Allen AN, O'Briant K, Schummer M, Karlan B, Urban ND, Tewari M et al..  2010.  Activation of the MEK-S6 pathway in high-grade ovarian cancers.. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. 18(6):499-508. Abstract
U
Urban ND, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, Paley P, Drescher CW.  2012.  Interpretation of Single and Serial Measures of HE4 and CA125 in Asymptomatic Women at High Risk for Ovarian Cancer.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 21(11):2087-94. Abstract
Urban ND.  2011.  Designing early detection programs for ovarian cancer.. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 22 Suppl 8:viii6-viii18. Abstract
Urban ND, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, Scholler N, O'Briant KC, Anderson GL, Cramer DW, Berg CD et al..  2011.  Potential Role of HE4 in Multimodal Screening for Epithelial Ovarian Cancer.. Journal of the National Cancer Institute. 103(21):1630-4. Abstract
Urban ND, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, Manson JE, Palomares MR, Daly MB, Wactawski-Wende J et al..  2015.  Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.. Gynecologic oncology. 139(2):253-260. Abstract
S
Swisher EM, Sakai W, Karlan BY, Wurz K, Urban ND, Taniguchi T.  2008.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.. Cancer research. 68(8):2581-6. Abstract
Strauss R, Li Z-Y, Liu Y, Beyer I, Persson J, Sova P, Möller T, Pesonen S, Hemminki A, Hamerlik P et al..  2011.  Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity.. PloS one. 6(1):e16186. Abstract
Strauss R, Sova P, Liu Y, Li ZY, Tuve S, Pritchard D, Brinkkoetter P, Möller T, Wildner O, Pesonen S et al..  2009.  Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.. Cancer research. 69(12):5115-25. Abstract
Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD et al..  2009.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72. Abstract
Schummer M, Green A, Beatty JD, Karlan BY, Karlan S, Gross J, Thornton S, McIntosh MW, Urban ND.  2010.  Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection.. PloS one. 5(2):e9122. Abstract
Schummer M, Thorpe J, Giraldez M, Bergan L, Tewari M, Urban ND.  2015.  Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.. PloS one. 10(11):e0142911. Abstract
Schummer M, Beatty JD, Urban ND.  2010.  Breast cancer genomics: normal tissue and cancer markers.. Annals of the New York Academy of Sciences. 1210:78-85. Abstract
Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellström I, Hellström KE, Urban ND.  2012.  Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.. Gynecologic oncology. 125(1):65-69. Abstract
Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose PV et al..  2015.  Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.. Journal of the National Cancer Institute. 107(4) Abstract
Scholler N, Gross JA, Garvik B, Wells L, Liu Y, Loch CM, Ramirez AB, McIntosh MW, Lampe PD, Urban ND.  2008.  Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery.. Journal of translational medicine. 6:41. Abstract
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ et al..  2008.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.. Nature. 451(7182):1116-20. Abstract
R
Richter M, Yumul R, Wang H, Saydaminova K, Ho M, May D, Baldessari A, Gough M, Drescher C, Urban ND et al..  2015.  Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.. Molecular therapy. Methods & clinical development. 2:15005. Abstract
Ramirez AB, Loch CM, Zhang Y, Liu Y, Wang X, Wayner EA, Sargent JE, Sibani S, Hainsworth E, Mendoza EA et al..  2010.  Use of a single-chain antibody library for ovarian cancer biomarker discovery.. Molecular & cellular proteomics : MCP. 9(7):1449-60. Abstract
P
Pocobelli G, Chubak J, Hanson N, Drescher C, Resta R, Urban ND, Buist DSM.  2012.  Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling.. Gynecologic oncology. Abstract